Predicting In-Hospital Treatment Failure (≤ 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids

COPD. 2016;13(1):82-92. doi: 10.3109/15412555.2015.1057276. Epub 2015 Oct 9.

Abstract

Although pharmacological treatment of COPD exacerbation (COPDE) includes antibiotics and systemic steroids, a proportion of patients show worsening of symptoms during hospitalization that characterize treatment failure. The aim of our study was to determine in-hospital predictors of treatment failure (≤ 7 days). Prospective data on 110 hospitalized COPDE patients, all treated with antibiotics and systemic steroids, were collected; on the seventh day of hospitalization, patients were divided into treatment failure (n = 16) or success (n = 94). Measures of inflammatory serum biomarkers were recorded at admission and at day 3; data on clinical, laboratory, microbiological, and severity, as well data on mortality and readmission, were also recorded. Patients with treatment failure had a worse lung function, with higher serum levels of C-reactive protein (CRP), procalcitonin (PCT), tumour necrosis factor-alpha (TNF-α), interleukin (IL) 8, and IL-10 at admission, and CRP and IL-8 at day 3. Longer length of hospital stay and duration of antibiotic therapy, higher total doses of steroids and prevalence of deaths and readmitted were found in the treatment failure group. In the multivariate analysis, +1 mg/dL of CRP at admission (OR, 1.07; 95% CI, 1.01 to 1.13) and use of penicillins or cephalosporins (OR, 5.63; 95% CI, 1.26 to 25.07) were independent variables increasing risk of treatment failure, whereas cough at admission (OR, 0.20; 95% CI, 0.05 to 0.75) reduces risk of failure. In hospitalized COPDE patients CRP at admission and use of specific class of antibiotics predict in-hospital treatment failure, while presence of cough has a protective role.

Keywords: Chronic obstructive pulmonary disease; disease exacerbation; inflammatory response; predictors; treatment failure.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • C-Reactive Protein / metabolism
  • Calcitonin / metabolism
  • Calcitonin Gene-Related Peptide
  • Cohort Studies
  • Disease Progression
  • Female
  • Forced Expiratory Volume
  • Glucocorticoids / therapeutic use*
  • Hospitalization*
  • Humans
  • Interleukin-1 / metabolism
  • Interleukin-10 / metabolism
  • Interleukin-6 / metabolism
  • Interleukin-8 / metabolism
  • Length of Stay / statistics & numerical data
  • Logistic Models
  • Male
  • Mental Status Schedule
  • Middle Aged
  • Mortality
  • Multivariate Analysis
  • Patient Readmission / statistics & numerical data
  • Pneumonia, Bacterial / drug therapy
  • Prognosis
  • Prospective Studies
  • Protein Precursors / metabolism
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / metabolism
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Risk Factors
  • Time Factors
  • Treatment Failure
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Anti-Bacterial Agents
  • CALCA protein, human
  • CXCL8 protein, human
  • Glucocorticoids
  • IL10 protein, human
  • IL6 protein, human
  • Interleukin-1
  • Interleukin-6
  • Interleukin-8
  • Protein Precursors
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Calcitonin
  • C-Reactive Protein
  • Calcitonin Gene-Related Peptide